Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin in Obstructive Sleep Apnea
NCT03148899Phase 2Completed
- Sponsor
- George Washington University
- Start
- Jul 2016
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in obstructive sleep apnea (OSA), sponsored by George Washington University. Primary endpoint: Duration of Obstructive Events at Day 29. Started Jul 2016; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03148899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148899.